Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
about
Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity.Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1β production.
P2860
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Bortezomib Improves Adoptive T ...... er Cells to FasL Cytotoxicity.
@ast
Bortezomib Improves Adoptive T ...... er Cells to FasL Cytotoxicity.
@en
type
label
Bortezomib Improves Adoptive T ...... er Cells to FasL Cytotoxicity.
@ast
Bortezomib Improves Adoptive T ...... er Cells to FasL Cytotoxicity.
@en
prefLabel
Bortezomib Improves Adoptive T ...... er Cells to FasL Cytotoxicity.
@ast
Bortezomib Improves Adoptive T ...... er Cells to FasL Cytotoxicity.
@en
P2093
P2860
P1433
P1476
Bortezomib Improves Adoptive T ...... er Cells to FasL Cytotoxicity.
@en
P2093
Alan D Brooks
Anil Shanker
Dan L Longo
Daniel W McVicar
Duafalia F Dudimah
Menaka C Thounaojam
Rachel L de Kluyver
Samuel T Pellom
Thomas J Sayers
William J Murphy
P2860
P304
P356
10.1158/0008-5472.CAN-15-0794
P407
P50
P577
2015-10-22T00:00:00Z